<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; commission</title>
	<atom:link href="http://www.tapanray.in/tag/commission/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>With Frugal Public Resource Allocation Quo Vadis Healthcare in India?</title>
		<link>http://www.tapanray.in/with-frugal-public-resource-allocation-quo-vadis-healthcare-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=with-frugal-public-resource-allocation-quo-vadis-healthcare-in-india</link>
		<comments>http://www.tapanray.in/with-frugal-public-resource-allocation-quo-vadis-healthcare-in-india/#comments</comments>
		<pubDate>Mon, 16 Mar 2015 00:00:12 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[14th]]></category>
		<category><![CDATA[2014-15]]></category>
		<category><![CDATA[2015-16]]></category>
		<category><![CDATA[Budget]]></category>
		<category><![CDATA[commission]]></category>
		<category><![CDATA[erstwhile]]></category>
		<category><![CDATA[expenditure]]></category>
		<category><![CDATA[Finance]]></category>
		<category><![CDATA[frugalNational]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[OECD]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Planning]]></category>
		<category><![CDATA[Policy 2015]]></category>
		<category><![CDATA[quo vadis]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Union]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6448</guid>
		<description><![CDATA[The memory is still afresh in India. A new political dispensation took charge of the governance of the country, riding on the tidal waves of people’s hope and aspirations, with presumed credibility to ‘Walk the Talk’. The expectations were skyrocketing &#8230; <a href="http://www.tapanray.in/with-frugal-public-resource-allocation-quo-vadis-healthcare-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/with-frugal-public-resource-allocation-quo-vadis-healthcare-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>With Free Medicines In, Would The New Government Revisit ‘Universal Health Coverage’ Soon?</title>
		<link>http://www.tapanray.in/with-free-medicines-in-would-the-new-government-revisit-universal-health-coverage-soon/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=with-free-medicines-in-would-the-new-government-revisit-universal-health-coverage-soon</link>
		<comments>http://www.tapanray.in/with-free-medicines-in-would-the-new-government-revisit-universal-health-coverage-soon/#comments</comments>
		<pubDate>Mon, 02 Jun 2014 00:00:19 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[CMSS]]></category>
		<category><![CDATA[commission]]></category>
		<category><![CDATA[consulting]]></category>
		<category><![CDATA[Coverage]]></category>
		<category><![CDATA[distribution]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[expenditure]]></category>
		<category><![CDATA[Free]]></category>
		<category><![CDATA[harsh]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[HLEG]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[IMS]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[insurance]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[Manmohan]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Obamacare]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[oop]]></category>
		<category><![CDATA[OP]]></category>
		<category><![CDATA[out]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PHC]]></category>
		<category><![CDATA[PHFI]]></category>
		<category><![CDATA[Planning]]></category>
		<category><![CDATA[pocket]]></category>
		<category><![CDATA[Rajasthan]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reddy]]></category>
		<category><![CDATA[Singh]]></category>
		<category><![CDATA[Srinath]]></category>
		<category><![CDATA[Tamil Nadu]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[UHC]]></category>
		<category><![CDATA[Universal]]></category>
		<category><![CDATA[Vardhan]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5462</guid>
		<description><![CDATA[Friday last, the new Union Health Minister Dr. Harsh Vardhan reportedly announced that the his ministry would soon start work on distributing free medicines through public hospitals across the country. For this purpose the Minister would soon call a meeting of the &#8230; <a href="http://www.tapanray.in/with-free-medicines-in-would-the-new-government-revisit-universal-health-coverage-soon/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/with-free-medicines-in-would-the-new-government-revisit-universal-health-coverage-soon/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Big Pharma Receives Another Body Blow: Would Indian Slumber End Now?</title>
		<link>http://www.tapanray.in/big-pharma-receives-another-body-blow-would-indian-slumber-end-now/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=big-pharma-receives-another-body-blow-would-indian-slumber-end-now</link>
		<comments>http://www.tapanray.in/big-pharma-receives-another-body-blow-would-indian-slumber-end-now/#comments</comments>
		<pubDate>Mon, 19 May 2014 00:00:59 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[B]]></category>
		<category><![CDATA[big]]></category>
		<category><![CDATA[blow]]></category>
		<category><![CDATA[body]]></category>
		<category><![CDATA[bribery]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[CME]]></category>
		<category><![CDATA[commission]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[glaxo]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[hepatitis]]></category>
		<category><![CDATA[Heptodin]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[J&J]]></category>
		<category><![CDATA[Mark]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[Parliamentary]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[PIL]]></category>
		<category><![CDATA[Planning]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[receives]]></category>
		<category><![CDATA[Reily]]></category>
		<category><![CDATA[rip-off]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[slumber]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Teva]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[Wake-up]]></category>
		<category><![CDATA[Xinhua]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5407</guid>
		<description><![CDATA[On May 13, 2014, The New York Times reported, while major pharmaceutical companies have been facing increased scrutiny of their marketing practices from governments around the world, last Wednesday the Chinese authorities sent a strong warning to the pharmaceutical industry &#8230; <a href="http://www.tapanray.in/big-pharma-receives-another-body-blow-would-indian-slumber-end-now/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/big-pharma-receives-another-body-blow-would-indian-slumber-end-now/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Why Try To Reinvent The Wheel With So Much Of Hullabaloo?</title>
		<link>http://www.tapanray.in/why-try-to-reinvent-the-wheel-with-so-much-of-hullabaloo/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=why-try-to-reinvent-the-wheel-with-so-much-of-hullabaloo</link>
		<comments>http://www.tapanray.in/why-try-to-reinvent-the-wheel-with-so-much-of-hullabaloo/#comments</comments>
		<pubDate>Wed, 19 Mar 2014 00:00:07 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Ahluwalia]]></category>
		<category><![CDATA[authorized]]></category>
		<category><![CDATA[commission]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[HLEG]]></category>
		<category><![CDATA[hullabaloo]]></category>
		<category><![CDATA[IMS]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Montek]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PHFI]]></category>
		<category><![CDATA[Planning]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reddy]]></category>
		<category><![CDATA[reinvent]]></category>
		<category><![CDATA[Singh]]></category>
		<category><![CDATA[Srinath]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[UHC]]></category>
		<category><![CDATA[wheel]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5112</guid>
		<description><![CDATA[A recent IMS study, apparently ‘authorized’ (whatever it means) by the Planning Commission of India has reportedly suggested various ‘ways to make drugs affordable in India’. Though there does not appear to be anything new in the reported suggestions, the &#8230; <a href="http://www.tapanray.in/why-try-to-reinvent-the-wheel-with-so-much-of-hullabaloo/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/why-try-to-reinvent-the-wheel-with-so-much-of-hullabaloo/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Does the Landmark Glivec Judgment Discourage Innovation in India?</title>
		<link>http://www.tapanray.in/does-the-landmark-glivec-judgment-discourage-innovation-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=does-the-landmark-glivec-judgment-discourage-innovation-in-india</link>
		<comments>http://www.tapanray.in/does-the-landmark-glivec-judgment-discourage-innovation-in-india/#comments</comments>
		<pubDate>Mon, 08 Apr 2013 00:00:19 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[191]]></category>
		<category><![CDATA[2005]]></category>
		<category><![CDATA[3d]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[Case]]></category>
		<category><![CDATA[Challenges]]></category>
		<category><![CDATA[Cipal]]></category>
		<category><![CDATA[commission]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[Delhi]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[efficacy]]></category>
		<category><![CDATA[gefitinib. Roche]]></category>
		<category><![CDATA[Glenmark]]></category>
		<category><![CDATA[Glivec]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[highcourt]]></category>
		<category><![CDATA[incremental]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[innovative]]></category>
		<category><![CDATA[Innovators]]></category>
		<category><![CDATA[interpretation]]></category>
		<category><![CDATA[IPA]]></category>
		<category><![CDATA[IPO]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Janumet]]></category>
		<category><![CDATA[Januvia]]></category>
		<category><![CDATA[Judgment]]></category>
		<category><![CDATA[knowledge]]></category>
		<category><![CDATA[landmark]]></category>
		<category><![CDATA[medicines. imatinib]]></category>
		<category><![CDATA[mesylate]]></category>
		<category><![CDATA[MSD]]></category>
		<category><![CDATA[Natco]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[organization]]></category>
		<category><![CDATA[out]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[patentability]]></category>
		<category><![CDATA[pegasys]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[revocation]]></category>
		<category><![CDATA[section]]></category>
		<category><![CDATA[Socioeconomic]]></category>
		<category><![CDATA[step]]></category>
		<category><![CDATA[stutent]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[time]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[with]]></category>
		<category><![CDATA[wockhardt]]></category>
		<category><![CDATA[World]]></category>
		<category><![CDATA[Zita]]></category>
		<category><![CDATA[Zita-Met]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2150</guid>
		<description><![CDATA[No, I do not think so. The 112 pages well articulated judgment of the Supreme Court of India delivered on April 1, 2013, does not even remotely discourage innovation in India, including much talked about ‘incremental innovation’. This landmark judgment &#8230; <a href="http://www.tapanray.in/does-the-landmark-glivec-judgment-discourage-innovation-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/does-the-landmark-glivec-judgment-discourage-innovation-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>To Curb Pharma Marketing Malpractices in India Who Bells the Cat?</title>
		<link>http://www.tapanray.in/to-curb-pharma-marketing-malpractices-in-india-who-bells-the-cat/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=to-curb-pharma-marketing-malpractices-in-india-who-bells-the-cat</link>
		<comments>http://www.tapanray.in/to-curb-pharma-marketing-malpractices-in-india-who-bells-the-cat/#comments</comments>
		<pubDate>Mon, 18 Mar 2013 00:00:37 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[Australia]]></category>
		<category><![CDATA[bribe]]></category>
		<category><![CDATA[cat]]></category>
		<category><![CDATA[commission]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[curb]]></category>
		<category><![CDATA[curbing]]></category>
		<category><![CDATA[disclosure]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[E&Y]]></category>
		<category><![CDATA[financial]]></category>
		<category><![CDATA[Game]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[HHS]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[indictment]]></category>
		<category><![CDATA[inertia]]></category>
		<category><![CDATA[interest]]></category>
		<category><![CDATA[intriguing]]></category>
		<category><![CDATA[Japan]]></category>
		<category><![CDATA[Jyoti]]></category>
		<category><![CDATA[Law]]></category>
		<category><![CDATA[Malpractices]]></category>
		<category><![CDATA[Mirdha]]></category>
		<category><![CDATA[MoH]]></category>
		<category><![CDATA[mouse]]></category>
		<category><![CDATA[Netherlands]]></category>
		<category><![CDATA[Obama]]></category>
		<category><![CDATA[Parliament]]></category>
		<category><![CDATA[Parliamentary]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Payment]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Physician]]></category>
		<category><![CDATA[Planning]]></category>
		<category><![CDATA[Protection]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reform]]></category>
		<category><![CDATA[slovakia]]></category>
		<category><![CDATA[Standing]]></category>
		<category><![CDATA[Sunshine]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[transparency]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[UK]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2050</guid>
		<description><![CDATA[Bribing doctors by the pharmaceutical companies directly or indirectly, as reported frequently by the media all over the world, including India, to prescribe their respective brand of drugs has now reached an alarming proportion, jeopardizing patients’ interest, seriously more than &#8230; <a href="http://www.tapanray.in/to-curb-pharma-marketing-malpractices-in-india-who-bells-the-cat/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/to-curb-pharma-marketing-malpractices-in-india-who-bells-the-cat/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Credible role of CCI and NPPA should allay fear of possible ill effects of FDI in Pharmaceuticals</title>
		<link>http://www.tapanray.in/credible-role-of-cci-and-nppa-should-allay-fear-of-possible-ill-effects-of-fdi-in-pharmaceuticals/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=credible-role-of-cci-and-nppa-should-allay-fear-of-possible-ill-effects-of-fdi-in-pharmaceuticals</link>
		<comments>http://www.tapanray.in/credible-role-of-cci-and-nppa-should-allay-fear-of-possible-ill-effects-of-fdi-in-pharmaceuticals/#comments</comments>
		<pubDate>Sun, 07 Aug 2011 23:30:32 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[allay]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[CCI]]></category>
		<category><![CDATA[commission]]></category>
		<category><![CDATA[competition]]></category>
		<category><![CDATA[Credible]]></category>
		<category><![CDATA[direct]]></category>
		<category><![CDATA[effects]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[fear]]></category>
		<category><![CDATA[foreign]]></category>
		<category><![CDATA[ill]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[investments]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Possible]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[role]]></category>
		<category><![CDATA[Should]]></category>
		<category><![CDATA[Tapan]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=218</guid>
		<description><![CDATA[On August 3, 2011, ‘The Hindu Business Line’ reported, “Domestic drug-makers worried by side-effects of MNC buyouts.” It opined, “Acquisitions in the pharma industry came in for sharp focus, after several domestic drug-makers sold their operations partially or entirely to &#8230; <a href="http://www.tapanray.in/credible-role-of-cci-and-nppa-should-allay-fear-of-possible-ill-effects-of-fdi-in-pharmaceuticals/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/credible-role-of-cci-and-nppa-should-allay-fear-of-possible-ill-effects-of-fdi-in-pharmaceuticals/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Limiting FDI in Pharma is a protectionist cry: Does not benefit the common man.</title>
		<link>http://www.tapanray.in/limiting-fdi-in-pharma-is-a-protectionist-cry-does-not-benefit-the-common-man/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=limiting-fdi-in-pharma-is-a-protectionist-cry-does-not-benefit-the-common-man</link>
		<comments>http://www.tapanray.in/limiting-fdi-in-pharma-is-a-protectionist-cry-does-not-benefit-the-common-man/#comments</comments>
		<pubDate>Sat, 08 Jan 2011 16:30:24 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[100%]]></category>
		<category><![CDATA[49%]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[automatic]]></category>
		<category><![CDATA[benefit]]></category>
		<category><![CDATA[CCI]]></category>
		<category><![CDATA[commission]]></category>
		<category><![CDATA[common]]></category>
		<category><![CDATA[competition]]></category>
		<category><![CDATA[cry]]></category>
		<category><![CDATA[DIPP]]></category>
		<category><![CDATA[direct]]></category>
		<category><![CDATA[Does]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[investments]]></category>
		<category><![CDATA[is]]></category>
		<category><![CDATA[Limiting]]></category>
		<category><![CDATA[man. foreign]]></category>
		<category><![CDATA[Not]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[protectionist]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[route]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=317</guid>
		<description><![CDATA[“Protectionism is harmful” very aptly commented by Mr. Pranab Mukherjee, the Finance Minister of India, just the other day. This was in context of “recent US moves to hike visa fees and clamp down on outsourcing”. While almost at the &#8230; <a href="http://www.tapanray.in/limiting-fdi-in-pharma-is-a-protectionist-cry-does-not-benefit-the-common-man/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/limiting-fdi-in-pharma-is-a-protectionist-cry-does-not-benefit-the-common-man/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
